Analyst Ratings For Cara Therapeutics Inc (NASDAQ:CARA)
Today, Janney Montgomery Scott initiated coverage on Cara Therapeutics Inc (NASDAQ:CARA) with a Buy.
There are 9 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Cara Therapeutics Inc (NASDAQ:CARA) is Buy with a consensus target price of $26.1111 per share, a potential 103.52% upside.
Some recent analyst ratings include
- 12/20/2018-Cara Therapeutics Inc (NASDAQ:CARA) has coverage initiated with a Buy rating
- 9/13/2018-Cara Therapeutics Inc (NASDAQ:CARA) has coverage initiated with a Buy ➝ Buy rating and $30.00 price target
- On 11/15/2018 Mani Mohindru, CFO, sold 16,042 with an average share price of $18.50 per share and the total transaction amounting to $296,777.00.
- On 11/1/2018 Derek T Chalmers, CEO, sold 20,000 with an average share price of $18.78 per share and the total transaction amounting to $375,600.00.
- On 11/1/2018 Frederique Ph.D. Menzaghi, SVP, sold 3,000 with an average share price of $18.77 per share and the total transaction amounting to $56,310.00.
- On 10/17/2018 Joseph William Stauffer, Insider, sold 11,442 with an average share price of $20.13 per share and the total transaction amounting to $230,327.46.
- On 10/17/2018 Mani Mohindru, CFO, sold 16,042 with an average share price of $20.19 per share and the total transaction amounting to $323,887.98.
- On 10/1/2018 Derek T Chalmers, CEO, sold 20,000 with an average share price of $23.79 per share and the total transaction amounting to $475,800.00.
- On 10/1/2018 Frederique Ph.D. Menzaghi, SVP, sold 3,000 with an average share price of $23.99 per share and the total transaction amounting to $71,970.00.
About Cara Therapeutics Inc (NASDAQ:CARA)
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Recent Trading Activity for Cara Therapeutics Inc (NASDAQ:CARA)
Shares of Cara Therapeutics Inc closed the previous trading session at 12,90 −0,46 3,44 % with 13.7 shares trading hands.
